Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 16 results.
User Information
Export Records
  1. 1.   Immunological monitoring of the tumor immunoenvironment for clinical trials
  2. Malyguine, A. M.; Strobl, S. L.; Shurin, M. R.
  3. Cancer Immunology Immunotherapy. 2012, Feb; 61(2): 239-247.
  1. 2.   New flow cytometric assays for monitoring cell-mediated cytotoxicity
  2. Zaritskaya, L.; Shurin, M. R.; Sayers, T. J.; Malyguine, A. M.
  3. Expert Review of Vaccines. 2010, Jun; 9(6): 601-616.
  1. 3.   Antigen Presented by Tumors In vivo Determines the Nature of CD8(+) T-Cell Cytotoxicity
  2. Shanker, A.; Brooks, A. D.; Jacobsen, K. M.; Wine, J. W.; Wiltrout, R. H.; Yagita, H.; Sayers, T. J.
  3. Cancer Research. 2009 69(16): 6615-6623.
  1. 4.   Application of a Flow Cytometric Cytotoxicity Assay for Monitoring Cancer Vaccine Trials
  2. Zaritskaya, L.; Shafer-Weaver, K. A.; Gregory, M. K.; Strobl, S. L.; Baseler, M.; Malyguine, A.
  3. Journal of Immunotherapy. 2009 32(2): 186-194.
  1. 5.   The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death
  2. Hodge, D. L.; Subleski, J. J.; Reynolds, D. A.; Buschman, M. D.; Schill, W. B.; Burkett, M. W.; Malyguine, A. M.; Young, H. A.
  3. Journal of Interferon and Cytokine Research. 2006, Oct; 26(10): 706-718.
  1. 6.   NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function
  2. Abdool, K.; Cretney, E.; Brooks, A. D.; Kelly, J. M.; Swann, J.; Shanker, A.; Bere, E. W.; Yokoyama, W. M.; Ortaldo, J. R.; Smyth, M. J.; Sayers, T. J.
  3. Journal of Immunology. 2006, Aug; 177(4): 2575-2583.
  1. 7.   A novel flow cytometric assay for evaluating cell-mediated cytotoxicity
  2. Burkett, M. W.; Weaver, K. A. S.; Strobl, S.; Baseler, M.; Malyguine, A.
  3. Journal of Immunotherapy. 2005, JUL-AUG; 28(4): 396-402.
  1. 8.   Comparison of benchtop microplate beta counters with the traditional gamma counting method for measurement of chromium-51 release in cytotoxic assays
  2. Wallace, D.; Hildesheim, A.; Pinto, L. A.
  3. Clinical and Diagnostic Laboratory Immunology. 2004 11(2): 255-260.
  1. 9.   Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils
  2. Kamohara, H.; Matsuyama, W.; Shimozato, O.; Abe, K.; Galligan, C.; Hashimoto, S. I.; Matsushima, K.; Yoshimura, T.
  3. Immunology. 2004 111(2): 186-194.
  1. 10.   Study of diverse mechanisms of cell-mediated cytotoxicity in gene-targeted mice using flow cytometric cytotoxicity assay
  2. Malyguine, A.; Derby, E.; Brooks, A.; Reddy, V.; Baseler, M.; Sayers, T.
  3. Immunology Letters. 2002 83(1): 55-59.
  1. 11.   Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis
  2. Smyth, M. J.; Cretney, E.; Takeda, K.; Wiltrout, R. H.; Sedger, L. M.; Kayagaki, N.; Yagita, H.; Okumura, K.
  3. Journal of Experimental Medicine. 2001 193(6): 661-670.
  1. 12.   Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity
  2. Derby, E.; Reddy, V.; Kopp, W.; Nelson, E.; Baseler, M.; Sayers, T.; Malyguine, A.
  3. Immunology Letters. 2001 78(1): 35-39.
  1. 13.   IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
  2. Wigginton, J. M.; Gruys, E.; Geiselhart, L.; Subleski, J.; Komschlies, K. L.; Park, J. W.; Wiltrout, T. A.; Nagashima, K.; Back, T. C.; Wiltrout, R. H.
  3. Journal of Clinical Investigation. 2001 108(1): 51-62.
  1. 14.   T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas
  2. Sayers, T. J.; Brooks, A. D.; Seki, N.; Smyth, M. J.; Yagita, H.; Blazar, B. R.; Malyguine, A. M.
  3. Journal of Leukocyte Biology. 2000 68(1): 81-86.
  1. 15.   Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: Impaired NK cell development and recruitment
  2. Ito, D.; Back, T. C.; Shakhov, A. N.; Wiltrout, R. H.; Nedospasov, S. A.
  3. Journal of Immunology. 1999 163(5): 2809-2815.
  1. 16.   P-4 and Rnkp-7, New Granzyme-Like Serine Proteases Expressed in Activated Rat Lymphocytes
  2. Ewoldt, G. R.; Smyth, M. J.; Darcy, P. K.; Harris, J. L.; Craik, C. S.; Horowitz, B.; Woodard, S. L.; Powers, J. C.; Hudig, D.
  3. Journal of Immunology. 1997 158(10): 4574-4583.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel